Auditors have determined that the federal Medicare program has spent billions of dollars on implantable medical devices that fail to work as intended, including $1.5 billion related to seven recalled heart devices made by three companies with deep Minnesota ties.
In response to a Freedom of Information Act request, auditors with Medicare's financial watchdog office have told the Star Tribune they are auditing expenses related to problem-prone heart devices made by Medtronic PLC, St. Jude Medical, Inc. and Boston Scientific Corp.
The seven specific devices under investigation in the ongoing audit include defective or recalled pacemakers, implantable defibrillators and the wires called "leads" that connect them to the heart.
"We selected these devices with no intent ... to target any device manufacturer," the auditors' office said in its FOIA response.
The audit is investigating expenses generated by recalls of Medtronic's Concerto, Virtuoso and EnTrust defibrillators; St. Jude's Riata leads and Identity pacemaker; and Boston Scientific's Teligen and Cognis defibrillators. All three companies employ thousands of Minnesotans.
Medtronic and Boston Scientific said in statements that they stand behind their products with warranties and that patient safety is a core company concern.
"It is incorrect to assume that Medtronic profits from devices that reportedly malfunction," a Medtronic spokesman said via e-mail. He added that "when there is an issue with a device, Medtronic stands behind them through robust warranties, which often include replacement devices and reasonable out of pocket medical expenses for the patients."
St. Jude, which is being acquired by Abbott Laboratories in a $25 billion deal, didn't provide a response to questions about the audit.